Healthcare Apr 26, 2022 03:43 PM (GMT+8) · EqualOcean
On April 26, 2022, the inactivated vaccine of Sinopharm China biological Omicron mutant novel coronavirus was approved by the State Food and drug administration. Sinopharm China Bio introduced the Omicron variant strain from the University of Hong Kong for the first time and launched the research and development of the inactivated vaccine of the Austrian strain on December 9, 2021, on the basis of the prototype strain Xinguan inactivated vaccine already on the market in the early stage and the research and development of the inactivated vaccine of beta and delta variant strain. On March 3, 2022, Beijing Institute of biological products and Wuhan Institute of biological products determined the clinical scheme and relevant details with Hong Kong research institutions. On April 1, they submitted clinical application materials to the Hong Kong Department of health. They obtained ethical approval on April 12 and clinical research approval on April 13, becoming the first inactivated vaccine of Omicron strain approved for clinical use in the world.